At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Panitumumab +4 moredrug
Likely dose
Panitumumab 6 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
In Brief
A Phase 2 clinical trial evaluating Panitumumab, Oxaliplatin, and 3 other interventions for Colorectal Cancer. Completed, enrolled 15 participants across 15 sites.
Detailed Summary
In this Phase II study the investigators plan to determine the overall response rate (ORR) of the combination of FOLFOXIRI plus panitumumab as first-line treatment of patients with liver-only metastatic KRAS wild-type colorectal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesUnited States
CollaboratorsAmgen
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartDec 2010
Primary CompletionMar 2014
TodayJul 2026
First PostedOct 22, 2010
Enrollment StartDec 1, 2010
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.7 years ago
Interventions
Panitumumabdrug
6 mg/kg, 60-90 minute IV infusion every 2 weeks
Oxaliplatindrug
85 mg/m2, 2-hour IV infusion every 2 weeks
Irinotecandrug
125 mg/m2, 1-hour IV infusion every 2 weeks
Leucovorindrug
200 mg/m2, 2-hour IV infusion every 2 weeks
5-Fluorouracildrug
3200 mg/m2 IV, 48-hour continuous infusion every two weeks